No description
-
2018 (v1)PublicationUploaded on: April 14, 2023
-
2018 (v1)Publication
The original version of this article unfortunately contained a mistake.
Uploaded on: April 14, 2023 -
2020 (v1)Publication
Infections due to multidrug-resistant Gram-negative bacteria (MDR-GNB), especially when carbapenem resistant, have been very difficult to manage in the last fifteen years, owing to the paucity of dependable therapeutic options. Cefiderocol is a siderophore cephalosporin recently approved by the Food and Drug Administration (FDA) and European...
Uploaded on: April 14, 2023 -
2021 (v1)Publication
Colistin is a last-resort agent for the treatment of infections due to Gram-negative bacteria with difficult-to-treat resistance. The primary objective of this post hoc analysis of a cross-sectional study conducted in 22 Italian hospitals was to assess factors associated with inadequate intravenous colistin dosage. Overall, 187 patients...
Uploaded on: February 11, 2024 -
2018 (v1)Publication
Objectives: To analyze risk factors for early and late mortality in individuals aged 75 and older with Staphylococcus aureus bacteremia (SAB) in Italy. Design: Four-year retrospective observational study (January 2011-December 2014). Setting: Two tertiary care university hospitals in Italy (Santa Maria Misericordia Hospital in Udine,...
Uploaded on: April 14, 2023 -
2018 (v1)Publication
Introduction: Ceftolozane/tazobactam (C/T) is a new antibiotic resulting from the combination of a novel cephalosporin, structurally similar to ceftazidime, with tazobactam, a well-known beta-lactamase inhibitor. C/T remains active against extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae and multi-drug resistant (MDR) P....
Uploaded on: April 14, 2023 -
2019 (v1)Publication
Introduction: Ceftobiprole is a fifth-generation cephalosporin with a broad spectrum of antimicrobial activity, including also methicillin-resistant Staphylococcus aureus (MRSA). Ceftobiprole is approved for the treatment of community-acquired pneumonia (CAP) and hospital-acquired pneumonia (HAP), excluding ventilator-associated pneumonia, in...
Uploaded on: April 14, 2023 -
2015 (v1)Publication
The antibiotic pipeline continues to diminish and the majority of the public remains unaware of this critical situation. The cause of the decline of antibiotic development is multifactorial and currently most ICUs are confronted with the challenge of multidrug-resistant organisms. Antimicrobial multidrug resistance is expanding all over the...
Uploaded on: April 14, 2023 -
2014 (v1)Publication
No description
Uploaded on: April 14, 2023 -
2014 (v1)Publication
No description
Uploaded on: March 27, 2023 -
2014 (v1)Publication
Purpose: Candida is the most common cause of severe yeast infections worldwide, especially in critically ill patients. In this setting, septic shock attributable to Candida is characterized by high mortality rates. The aim of this multicenter study was to investigate the determinants of outcome in critically ill patients with septic shock due...
Uploaded on: April 14, 2023 -
2019 (v1)Publication
This study describes the largest clinical experience using ceftolozane/tazobactam (C/T) for different Pseudomonas aeruginosa infections. A retrospective study was performed at 22 hospitals in Italy (June 2016–March 2018). All adult patients treated with ≥4 days of C/T were enrolled. Successful clinical outcome was defined as complete resolution...
Uploaded on: April 14, 2023 -
2015 (v1)Publication
The increasing prevalence of colistin resistance (ColR) Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae (Kp) is a matter of concern because of its unfavourable impact on mortality of KPC-Kp bloodstream infections (BSI) and the shortage of alternative therapeutic options. A matched case-control-control analysis was conducted....
Uploaded on: March 27, 2023